Compare A & ARES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | A | ARES |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Managers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0B | 32.1B |
| IPO Year | 1999 | 2014 |
| Metric | A | ARES |
|---|---|---|
| Price | $173.82 | $123.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 20 |
| Target Price | ★ $181.05 | $145.15 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 11-23-2026 | 10-29-2026 |
| Dividend Yield | 0.57% | ★ 4.62% |
| EPS Growth | ★ 3.16 | N/A |
| EPS | ★ 3.55 | N/A |
| Revenue | $4,472,000,000.00 | ★ $4,755,618,000.00 |
| Revenue This Year | $7.95 | $2.08 |
| Revenue Next Year | $6.41 | $18.36 |
| P/E Ratio | ★ $50.12 | $78.35 |
| Revenue Growth | 6.43 | ★ 28.86 |
| 52 Week Low | $108.35 | $95.80 |
| 52 Week High | $178.21 | $181.19 |
| Indicator | A | ARES |
|---|---|---|
| Relative Strength Index (RSI) | 58.50 | 56.79 |
| Support Level | $163.32 | $118.91 |
| Resistance Level | $177.05 | $129.65 |
| Average True Range (ATR) | 4.97 | 3.67 |
| MACD | -0.38 | 1.18 |
| Stochastic Oscillator | 66.51 | 98.81 |
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Ares Management is one of the world's largest alternative-asset managers, with $622.5 billion in total assets under management, or AUM, including $384.9 billion in fee-earning AUM, at the end of 2025. The company has four main business segments: credit strategies ($406.9 billion in total AUM and $249.8 billion in fee-earning AUM), private equity, ($25.3 billion/$14.4 billion), real estate/real assets ($139.1 billion/$84.1 billion), and other alternatives ($51.2 billion/$36.6 billion). The firm primarily serves institutional investors (80% of AUM) and high-net-worth individuals (20%). Ares operates through more than 35 offices in over 15 countries around the globe.